Palatability of a 125 μg, 250 μg and 500 μg roflumilast suspension in healthy subjects – a double-blind, placebo-controlled, 4-period change-over study

*Please Note* The Study you are attempting to view was acquired from Takeda by AstraZeneca and was disclosed initially by Takeda per their Transparency Policies. More information regarding this study may be available by contacting [email protected].

A double-blind, placebo-controlled, four-period change-over study in healthy male subjects.